Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cure Pharmaceutical Holding Corp. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner, JANOSKO, CHASITY PAIGE, who holds 1 busiest examiner pending action. The matter is situated within 1 distinct art unit, indicating a specific technical focus for the company's current patenting efforts.
For a practitioner, the presence of only 1 pending office action means that the portfolio's immediate growth is tied to a single examiner's decision. JANOSKO, CHASITY PAIGE serves as the sole point of contact, and her 1 busiest examiner pending action accounts for the entire active workload. The matching count of 1 pending office action and 1 distinct examiner in 1 distinct art unit suggests a streamlined but high-stakes prosecution environment. Without other pending matters to provide a baseline for examiner behavior in this technology area, the practitioner must focus entirely on the specific requirements of this 1 distinct examiner. The concentration in 1 distinct art unit further emphasizes the need for a targeted strategy that addresses the specific examination standards of that unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758215 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | JANOSKO, CHASITY PAIGE | 168d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758215 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | JANOSKO, CHASITY PAIGE | 168d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17758215 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | JANOSKO, CHASITY PAIGE | 1613 | §103 | Final Rejection | 168d overdue | Pending | Jun 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCure Pharmaceutical Holding Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chasity Paige Janosko has the most, with 1 of Cure Pharmaceutical Holding Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
